<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25393999</article-id><article-id pub-id-type="pmc">4224885</article-id><article-id pub-id-type="publisher-id">19490</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19490</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation &#x02013; Abstract O153</subject></subj-group></article-categories><title-group><article-title>Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-na&#x000ef;ve HIV-1-positive individuals: 96 week results from FLAMINGO</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Molina</surname><given-names>Jean-Michel</given-names></name><xref ref-type="aff" rid="AF0001_19490">1</xref></contrib><contrib contrib-type="author"><name><surname>Clotet</surname><given-names>Bonaventura</given-names></name><xref ref-type="aff" rid="AF0002_19490">2</xref></contrib><contrib contrib-type="author"><name><surname>van Lunzen</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="AF0003_19490">3</xref></contrib><contrib contrib-type="author"><name><surname>Lazzarin</surname><given-names>Adriano</given-names></name><xref ref-type="aff" rid="AF0004_19490">4</xref></contrib><contrib contrib-type="author"><name><surname>Cavassini</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="AF0005_19490">5</xref></contrib><contrib contrib-type="author"><name><surname>Henry</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="AF0006_19490">6</xref></contrib><contrib contrib-type="author"><name><surname>Kulagin</surname><given-names>Valeriv</given-names></name><xref ref-type="aff" rid="AF0007_19490">7</xref></contrib><contrib contrib-type="author"><name><surname>Givens</surname><given-names>Naomi</given-names></name><xref ref-type="aff" rid="AF0008_19490">8</xref></contrib><contrib contrib-type="author"><name><surname>Brennan</surname><given-names>Clare</given-names></name><xref ref-type="aff" rid="AF0009_19490">9</xref></contrib><contrib contrib-type="author"><name><surname>de Oliveira</surname><given-names>Carlos Fernando</given-names></name><xref ref-type="aff" rid="AF0010_19490">10</xref></contrib></contrib-group><aff id="AF0001_19490"><label>1</label>Service des Maladies, Infectieuses et Tropicales, H&#x000f4;pital Saint Louis, Paris, France</aff><aff id="AF0002_19490"><label>2</label>HIV Unit, Hospital Universitari Germans Trias i Pujol, Irsicaixa Foundation, UAB, UVIC-UCC, Badalona, Catalonia, Spain</aff><aff id="AF0003_19490"><label>3</label>Infectious Diseases Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany</aff><aff id="AF0004_19490"><label>4</label>Department of Infectious Diseases, IRCCS San Raffaele Via Stamira d'Ancona, Milan, Italy</aff><aff id="AF0005_19490"><label>5</label>Infectious Disease Service, Lausanne University Hospital, Lausanne, Switzerland</aff><aff id="AF0006_19490"><label>6</label>Department of Medicine, Hennepin County Medical Center, Minneapolis, MN, USA</aff><aff id="AF0007_19490"><label>7</label>Clinical Center for Prevention and Control of AIDS, Krasnodar, Russian Federation</aff><aff id="AF0008_19490"><label>8</label>Clinical Statistics, GlaxoSmithKline, Stockley Park, UK</aff><aff id="AF0009_19490"><label>9</label>Infectious Diseases, GlaxoSmithKline, Clinical Development, Research Triangle Park, NC, USA</aff><aff id="AF0010_19490"><label>10</label>PPD, Pharmacovigilance, Morrisville, NC, USA</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19490</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Molina Jean-Michel et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19490"><title>Introduction</title><p>Dolutegravir (DTG) 50 mg once daily was superior to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily through Week 48, with 90% vs. 83% of participants achieving HIV RNA 50 c/mL (<italic>p</italic>=0.025) [<xref rid="CIT0001_19490" ref-type="bibr">1</xref>]. We present data through Week 96.</p></sec><sec id="st2_19490"><title>Material and Methods</title><p>FLAMINGO is a multicentre, randomized, open-label, Phase IIIb non-inferiority study, in which HIV-1-positive ART-na&#x000ef;ve adults with HIV-1 RNA&#x02265;1000 c/mL and no evidence of viral resistance were randomized 1:1 to receive DTG or DRV/r, with investigator-selected backbone NRTIs (TDF/FTC or ABC/3TC). Participants were stratified by screening HIV-1 RNA (&#x02264;100K c/mL) and NRTI backbone.</p></sec><sec id="st3_19490"><title>Results</title><p>A total of 484 adults were randomized and treated; 25% had baseline HIV RNA 100K c/mL. At Week 96, the proportion of participants with HIV RNA 50 c/mL was 80% in the DTG arm vs. 68% in the DRV/r arm (adjusted difference 12.4%; 95% CI 4.7, 20.2%; <italic>p</italic>=0.002). Secondary analyses supported primary results: per-protocol [(DTG 83% vs. DRV/r 70%), 95% CI 12.9 (5.3, 20.6)] and treatment-related discontinuation = failure [(98% vs. 95%), 95% CI 3.2 (&#x02212;0.3, 6.7)]. Overall virologic non-response (DTG 8%; DRV/r 12%) and non-response due to other reasons (DTG 12%; DRV/r 21%) occurred less frequently on DTG. As at Week 48, the difference between arms was most pronounced in participants with high baseline viral load (82% vs. 52% response through Week 96) and in the TDF/FTC stratum (79% vs. 64%); consistent responses were seen in the ABC/3TC stratum (82% vs. 75%). Six participants (DTG 2, none post-Week 48; DRV/r 4, two post-Week 48) experienced protocol-defined virologic failure (PDVF; confirmed viral load 200 c/mL on or after Week 24); none had treatment-emergent resistance to study drugs. Most frequent drug-related adverse events (AEs) were diarrhoea, nausea and headache, with diarrhoea significantly more common on DRV/r (24%) than DTG (10%). Significantly more participants had Grade 2 fasting LDL toxicities on DRV/r (22%) vs. DTG (7%), <italic>p</italic>&#x0003c;0.001; mean changes in creatinine for DTG (~0.18 mg/dL) observed at Week 2 were stable through Week 96.</p></sec><sec id="st4_19490"><title>Conclusions</title><p>Once-daily DTG was superior to once-daily DRV/r in treatment-na&#x000ef;ve HIV-1-positive individuals, with no evidence of emergent resistance to DTG in virologic failure and relatively similar safety profiles for DTG and DRV/r through 96 Weeks.</p></sec></abstract></article-meta></front><back><ref-list><title>Reference</title><ref id="CIT0001_19490"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clotet</surname><given-names>B</given-names></name><name><surname>Feinberg</surname><given-names>J</given-names></name><name><surname>van Lunzen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Once-daily dolutegravir is superior to Darunavir + ritonavir in antiretroviral na&#x000ef;ve adults with HIV-1 Infection: 48 week results from the randomised study ING114915</article-title><source>Lancet</source><comment>Published Online April 1, 2014. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(14)60084-2">http://dx.doi.org/10.1016/S0140-6736(14)60084-2</ext-link></comment></element-citation></ref></ref-list></back></article>